TriSalus Life Sciences announced today that it enrolled the first patient in its clinical study of a treatment for metastatic uveal melanoma.
The PERIO-01 clinical study evaluates SD-101, an investigational toll-like receptor 9 (TLR9) agonist in adults with metastatic uveal melanoma through intravascular administration into uveal melanoma liver metastasis lesions in combination with checkpoint inhibitors using the novel pressure-enabled drug delivery (PEDD) approach.
Get the full story at our sister site, Drug Delivery Business News.
